Latest Breaking News On - New patent covering - Page 2 : comparemela.com

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS [December 29, 2020] MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS LA JOLLA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive multiple sclerosis (progressive MS).

Tokyo
Japan
Geoff-obrien
Yuichi-iwaki
Exchange-commission
Trademark-office
National-ms-society
Medicinova-inc
Nasdaq
Nova-receives-notice
New-patent-covering
Tokyo-stock-exchange